News

News 29.10.2026 Munich, Germany, and Schlieren-Zurich, Switzerland Preclinical program will evaluate Topadur’s proprietary, locally acting compounds, including clinical-stage TOP-N53, which target key disease processes in dystrophic Epidermolysis bullosa, a rare and debilitating genetic skin disorder DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and...

News 29.10.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics, (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited...

News 27.10.2026 ZURICH, Switzerland — October 26, 2026 — AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced new analyses from its global Phase 2 clinical trial (AP101-02) evaluating the company’s Phase...

News 26.10.2026 Zurich, 23 October  2026 – The auditing and consulting firm EY Switzerland’s Entrepreneur Of The Year 2026 award – the 29th year of the program – has been presented to Swiss business personalities in recognition of their innovation and commitment. Stefan Rösch-Rütsche, EY Switzerland’s Country Managing Partner, commented: “Swiss entrepreneurs make...

News 22.10.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the selection of MP0730 as its lead Radio-DARPin candidate targeting the...